Graviton BioScience has filed a notice of an exempt offering of securities to raise $24,999,996.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Graviton BioScience is raising up to $24,999,996.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Samuel Waksal played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Graviton BioScience
Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), along with other therapeutic compounds.
To learn more about Graviton BioScience, visit http://graviton.bio/
Contact:
Samuel Waksal, Chief Executive Officer
332-400-0444
https://www.linkedin.com/in/samuel-waksal-b2401815/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.